Forbes -
24 Jan 2019 22:24

Abbott Labs (NYSE:ABT) recently posted its Q4 results, which were in line with our estimates. Medical Devices continued to see steady sales growth, led by electrophysiology, and strong FreeStyle Libre sales. Established Pharmaceutical Products revenue were down in mid-single digits, primarily due...
Share this Article